Miruvor
Sign up
The short answer

What studies of Vitamin D and sun exposure found

38papers on Vitamin D and sun exposure
207people in 4 studies testing Vitamin D and sun exposure alone
3randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the placebo trial (low certainty): 2 findings, all B.

3 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, the randomised trial (very low certainty), for overall symptoms.

1 outcome rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, the placebo trial and compared with another group, not randomised (very low certainty): 4 findings, all D.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, Vitamin D and sun exposure may help, but the evidence is still limited. For long COVID and ME/CFS studied together, Vitamin D and sun exposure might help some people, but research can’t show it yet. For preventing long COVID, studies found little or no difference with Vitamin D and sun exposure. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 38 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Vitamin D and sun exposure · Long COVID is hereB
    May helpImprovement, low certainty
  3. Vitamin D and sun exposure · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Vitamin D and sun exposure · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Fatigue1 study · 40 people took Vitamin D and sun exposure Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (80 in all).

The placebo trial80 randomised · 8 weeks · 60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks

Fatigue improved more than in the comparison group.

Vitamin D and sun exposure may reduce fatigue in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (80 in all)
See the 1 study
  1. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial. (2024)

    People in the study
    80 randomised
    Dose
    60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks
    Outcome
    CFQ Chalder Fatigue Scale (CFQ-11)
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 40 people took Vitamin D and sun exposure Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (80 in all).

The placebo trial80 randomised · 8 weeks · 60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks

Low mood or anxiety improved more than in the comparison group.

Vitamin D and sun exposure may reduce low mood or anxiety in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (80 in all)
See the 1 study
  1. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial. (2024)

    People in the study
    80 randomised
    Dose
    60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks
    Outcome
    DASS–anxiety 21-item Depression, Anxiety, and Stress Scale (DASS-21)
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Cognition (brain fog)1 study · 40 people took Vitamin D and sun exposure Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 80 people found no clear difference; a small benefit can't be ruled out.

The placebo trial80 randomised · 8 weeks · 60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of vitamin D and sun exposure on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 80 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial. (2024)

    People in the study
    80 randomised
    Dose
    60,000 IU (total 480,000 IU over 8 weeks), once weekly for 8 weeks
    Outcome
    TMT A&B Trail Making Test A and B (TMT-A and TMT-B)
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Both together

Daily life and health overall

Overall symptoms1 study · 46 people took Vitamin D and sun exposure Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (85 in all).

The randomised trial91 randomised · 85 analysed · 24 weeks · 1.0 μg, once daily

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of vitamin D and sun exposure on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (85 in all)
See the 1 study
  1. Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial. (2026)

    People in the study
    91 randomised · 85 analysed
    Dose
    1.0 μg, once daily
    Outcome
    change in the number of ME/CFS symptoms from screening to Week 12
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Preventing long COVID

Symptoms

Fatigue1 study · 71 people took Vitamin D and sun exposure Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 144 people found no clear difference; a small benefit can't be ruled out; effect size 0.00 (very small).

The placebo trial240 randomised · 144 analysed · single dose · 200,000 IU, on the same day of randomization

No clear difference in fatigue.

The evidence is very uncertain about the effect of vitamin D and sun exposure on fatigue later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 144 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Vitamin D and sun exposure with placebo.

See the 1 study
  1. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19. (2022)

    People in the study
    240 randomised · 144 analysed
    Dose
    200,000 IU, on the same day of randomization
    Outcome
    Fatigue*
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High
Pain1 study · 71 people took Vitamin D and sun exposure Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 144 people found no clear difference; a small benefit can't be ruled out; effect size 0.00 (very small).

The placebo trial240 randomised · 144 analysed · single dose · 200,000 IU, on the same day of randomization

No clear difference in pain.

The evidence is very uncertain about the effect of vitamin D and sun exposure on pain later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 144 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Vitamin D and sun exposure with placebo.

See the 1 study
  1. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19. (2022)

    People in the study
    240 randomised · 144 analysed
    Dose
    200,000 IU, on the same day of randomization
    Outcome
    Joint pain*
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Daily life and health overall

Quality of life1 study · 71 people took Vitamin D and sun exposure Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 144 people found no clear difference; a small benefit can't be ruled out.

The placebo trial240 randomised · 144 analysed · single dose · 200,000 IU, on the same day of randomization

No clear difference in quality of life.

The evidence is very uncertain about the effect of vitamin D and sun exposure on quality of life later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 144 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19. (2022)

    People in the study
    240 randomised · 144 analysed
    Dose
    200,000 IU, on the same day of randomization
    Outcome
    QoL 36-Item Short Form Health Survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High
Overall symptoms1 study · 50 people took Vitamin D and sun exposure Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; effect size 0.00 (very small).

Compared with another group, not randomised132 in the study · more than 12 weeks after recovery · chronic

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of vitamin D and sun exposure on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Vitamin D and sun exposure with non-supplemented individuals.

See the 1 study
  1. EP280 - ECE_1881 - Chronic cholecalciferol supplementation and adequate vitamin D status are associated with reduced risk of long COVID (2026)

    People in the study
    132 in the study
    Dose
    chronic
    Outcome
    Long COVID occurrence in supplemented vs non-supplemented patients (entire cohort)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: 1:1 matched analysis for age, sex, comorbidities, and acute COVID-19 severity A 1:1 matched analysis for age, sex, comorbidities, and acute COVID-19 severity was performed
    Selection of participants
    Moderate. comparison group: 1:1 matched analysis for age, sex, comorbidities, and acute COVID-19 severity A 1:1 matched analysis for age, sex, comorbidities, and acute COVID-19 severity was performed
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Studies of combinations

Outcomes that only studies of Vitamin D and sun exposure given together with other treatments looked at. Shown, not graded: they can’t tell what Vitamin D and sun exposure did alone.

Fatigue ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): Chalder Fatigue Scale (CFQ), better.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Cognition (brain fog) ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): memory, item 11, and problems starting things, item 4, no clear difference.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Depression ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): total MADRS score, no clear difference.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Sleep ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): ISI, better.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Overall symptoms ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): CGI-I, better.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Daily functioning ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): WSAS, no clear difference.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Quality of life ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): individual measures of the SF-12, no clear difference.

Shown, not counted: Vitamin D and sun exposure was given together with other treatments.

Side effects

Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset3 studies
Dizziness1 study
Headache1 study

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial.2026 · placebo trial · 1,747 randomised
    Summary

    This parallel two-group randomized double-blinded trial enrolled 1747 adults with newly diagnosed COVID-19 in the United States and Mongolia (median age 38.0 y), cluster-randomized with up to one cohabiting contact each (277 household contacts). Index participants received oral vitamin D3 at 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk, or placebo. The primary outcome was at least one healthcare visit (including hospitalization) or death within 4 wk. The 4-wk cumulative incidence of healthcare utilization did not significantly differ: 0.28 in the vitamin D3 group (n = 863) compared with 0.29 in the placebo group (n = 884); OR 0.97 (95% CI: 0.75, 1.24). At 8 wk, per-protocol analysis showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID (OR 0.78; 95% CI: 0.59, 1.03). The authors reported similar nonsignificant results for the prespecified secondary treatment and prevention outcomes. No safety concerns were identified; withdrawals for harms were not reported. The authors state that promising results for long COVID warrant further study.

  2. Vitamin D3 Supplementation Enhances Symptom Relief and Modulates Microbiome and Immune Responses in Pediatric Post-Acute Sequelae of COVID-19: A Randomized Controlled Trial2026 · placebo trial · 33 randomised
    Summary

    This randomized, double-blind, placebo-controlled trial enrolled 33 children with pediatric post-acute sequelae of COVID-19 at China Medical University Children’s Hospital in Taiwan. Participants received oral vitamin D3 2,000 IU/day (Group A, n = 21) or placebo (Group B, n = 12) for six months. Outcomes assessed at baseline and 6 months included serum 25(OH)D, symptom severity on the Children’s Somatic Symptom Inventory-24, immune cytokines and checkpoint proteins, and nasal and rectal microbiota. The CSSI-24 decreased significantly in Group A (p < 0.05), with no notable change in Group B. Group A showed improvements in neuropsychiatric, respiratory, and cardiovascular symptoms compared with Group B. At 6 months, serum 25(OH)D was 27.35 ± 8.81 ng/mL in Group A and 29.41 ± 6.16 ng/mL in Group B, a difference reported as no longer significant; both groups increased from their own baseline (p < 0.01 for both). The authors reported that some participants withdrew mid-trial after symptom improvement or loss to follow-up. Side effects were not reported. The authors stated limitations including the small sample size (n = 33), limited statistical power and generalizability, and that the six-month duration may not capture long-term effects or optimal dosing.

  3. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial.2024 · placebo trial · 80 randomised
    Summary

    This randomized, double-blind, placebo-controlled trial asked whether high-dose vitamin D would reduce fatigue and neuropsychiatric symptoms in post-COVID syndrome. Eighty patients with post-COVID fatigue or neuropsychiatric symptoms were enrolled at Thammasat University Hospital, Thailand, between September 2022 and August 2023; 107 were assessed for eligibility and 80 underwent randomization, with 40 assigned to vitamin D and 40 to placebo. The vitamin D group received 60,000 IU oral vitamin D2 once weekly for 8 weeks (total 480,000 IU); the placebo group received a starch powder capsule once weekly for 8 weeks. Outcomes measured at baseline and 8 weeks included CFQ-11 fatigue, DASS-21 anxiety and depression, PSQI sleep, ACE-III cognition, TMT-A and TMT-B, IL-6, CRP, and vitamin D level. The vitamin D group showed significant improvements in CFQ (coefficient -3.5, P = 0.024), DASS-anxiety (coefficient -2.0, P = 0.011), and ACE (coefficient 2.1, P = 0.012). No significant differences were found in PSQI, DASS-depression, TMT, IL-6, or CRP. Forty vitamin D and 40 placebo participants were included in the analysis; two placebo participants missed the 8-week blood test but received the full intervention. No serious adverse events were reported. All adverse events occurred in 19 (47.5%) vitamin D and 12 (30%) placebo participants; dizziness in 7 (17.5%) vs 4 (10%), headache in 6 (15%) vs 5 (12.5%). Zero participants discontinued intervention.

  4. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19.2022 · placebo trial · 240 randomised · 144 analysed
    Summary

    This post-hoc, exploratory analysis came from a multicenter, double-blind, placebo-controlled, randomized clinical trial in two hospitals in São Paulo, Brazil, from 2 June 2020 to 27 August 2020. The trial randomized 240 hospitalized patients with moderate to severe COVID-19; 144 were included in this analysis (vitamin D3 n = 71; placebo n = 73). The vitamin D3 group received a single oral dose of 200,000 IU of vitamin D3 on the day of randomization; the placebo group received 10 ml of peanut oil solution. Discharged patients were followed for up to 1 year and evaluated by telephone interviews at 6 and 12 months. Outcomes were persistent or new symptoms and quality of life (QoL). No significant differences between the vitamin D3 and placebo groups were reported for cough, fatigue, fever, myalgia, joint pain, runny nose, nasal congestion, sore throat, hypertension, diabetes, cardiovascular disease, rheumatic disease, asthma, chronic obstructive pulmonary, chronic kidney disease, QoL, and new or persistent symptoms. Fever showed a significant main effect of time, with a reduction from baseline to 6 months (52 to 0) and 12 months (52 to 0) in the vitamin D3 group, and in the placebo group (53 to 0 at both times). The paper reports 8 withdrew consent in the vitamin D3 group and, in the placebo group, 1 withdrew consent and 3 died after hospital discharge; harms were not described. The authors state that the findings do not support the use of 200,000 IU of vitamin D3 compared to placebo for persistence or new symptoms and QoL.

  5. Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome--a randomised controlled trial.2015 · placebo trial · 50 randomised
    Summary

    This parallel-group, double-blind, randomised placebo-controlled trial tested whether high-dose intermittent oral vitamin D3 improved vascular health and fatigue in chronic fatigue syndrome. Fifty participants with chronic fatigue syndrome according to the Fukuda (1994) and Canadian (2003) criteria were randomised, 25 to oral vitamin D3 100,000 units every 2 months for 6 months and 25 to matching placebo. Participants were recruited from the Connective Tissue Disease Clinic at Ninewells Hospital, Dundee, Scotland, via advertising in the ME Research UK magazine and through local ME patient support groups. Outcomes were measured at baseline, 2 months and 6 months. The primary outcome was carotid-femoral pulse wave velocity. At 6 months, the adjusted treatment effect on pulse wave velocity was 0.0 m/s (95% CI -0.6 to 0.6; p=0.93), and on the Piper Fatigue scale total it was 0.2 points (95% CI -0.8 to 1.2; p=0.73). The paper reports no improvement in other vascular and metabolic outcomes. Table 6 lists 33 adverse events in the vitamin D group and 39 in the placebo group; one serious adverse event (a diagnosis of bowel cancer requiring hospitalisation) and a further diagnosis of ductal breast carcinoma in situ were noted in the vitamin D group. The authors found no evidence of worsening symptoms and no excess of adverse events in the treatment group. Limitations stated were that the trial was conducted in a single centre on an overwhelmingly white, adult cohort, so results cannot necessarily be generalised to other ethnic groups, children or other geographic areas; baseline imbalance and small size also made interpretation more difficult.

  6. Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial.2026 · randomised trial · 91 randomised · 85 analysed
    Summary

    This randomized, open-label, multicenter trial asked whether adding vitamin D replacement therapy guidance to an active vitamin D preparation improves ME/CFS symptoms in people who developed ME/CFS as post-vaccination syndrome (PVS) or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) and had serum 25(OH) vitamin D < 30 ng/mL. It enrolled 91 participants from five sites; 48 were assigned to the intervention group and 43 to the control group, and 85 were analysed (46 intervention, 39 control). The intervention was alfacalcidol 1.0 μg once daily plus a vitamin D supplement 25 μg once daily, dietary guidance, sun exposure guidance, and exercise therapy for 24 weeks. The control group received alfacalcidol 1.0 μg once daily plus general guidance for 12 weeks, then investigational treatment for 12 weeks. The primary endpoint was change in ME/CFS symptom count from screening to Week 12. Mean change was −6.7 in the intervention group versus −1.2 in the control group (between-group difference −5.6; 95% CI: −7.2, −3.9; p < 0.001). At Week 12, 16 intervention participants and 1 control participant achieved <8 symptoms (p < 0.001). Serum 25(OH) vitamin D change was 8.6 ng/mL versus −1.6 ng/mL (between-group difference 10.2 ng/mL; 95% CI: 7.9, 12.5). One control participant had two serious adverse events, acute pancreatitis and pancreatic cancer; a causal relationship with the active vitamin D preparation was ruled out. No cases of severe hypercalcemia or clinically significant renal function impairment were observed.

  7. Association of Vitamin D Supplementation with Glutathione Peroxidase (GPx) Activity, Interleukine-6 (IL-6) Levels, and Anxiety and Depression Scores in Patients with Post-COVID-19 Condition.2025 · randomised trial · 54 randomised
    Summary

    To evaluate differences associated with bolus and daily vitamin D3 supplementation, this prospective, interventional self-controlled study enrolled 54 participants with post-COVID-19 condition (PCC) from a post-COVID cohort at INER in Mexico; 28 received bolus oral cholecalciferol and 26 received daily oral cholecalciferol for 2 months (bolus once per week for eight weeks). The study compared bolus with daily supplementation; no placebo group was included. Assessed at baseline and day 60: GPx activity, IL-6 levels, Hospital Anxiety and Depression Scale scores, and cough, dyspnea and fatigue. GPx activity increased in all patients (p = 0.0001), the bolus group (p = 0.006) and the daily group (p = 0.01). The abstract states both regimens were associated with decreased IL-6, but the results text reports a significant decrease only in the bolus group (p = 0.01), with no significant change in all patients (p = 0.07) or the daily group (p = 0.30). Anxiety and depression scores decreased in all patients (p = 0.0001 and p = 0.001); bolus showed no significant differences (p > 0.05), daily showed significant decreases (p = 0.0001 for both), and between-group comparison showed a difference only in post-treatment anxiety (p = 0.01). Reductions were reported for cough (29.41%, 5/17), dyspnea (57.14%, 8/14) and fatigue (58.33%, 7/12); daily group improvements were not statistically significant (p > 0.05). No signs of toxicity or adverse effects were reported; withdrawals were not reported. The authors state that because this was a self-controlled study, further randomized controlled trials are needed.

  8. Chronic cholecalciferol supplementation and adequate vitamin D status are associated with reduced risk of Long COVID.2026 · compared with another group · 132 in the study
    Summary

    This retrospective observational study at IRCCS Ospedale San Raffaele, Milan, Italy, asked whether chronic cholecalciferol supplementation and 25(OH) vitamin D status relate to Long COVID. It included 132 adults with confirmed COVID-19 from March 2020 to May 2021 previously seen in an endocrine outpatient department; Long COVID was defined by NICE criteria at six months after acute disease recovery. Fifty patients received chronic cholecalciferol supplementation, maintained for the entire study period, with median supplementation 38 [28–83] months; 82 were not supplemented. In the entire cohort, Long COVID occurred in 7/50 14% vs 23/82 28% (p = 0.086). For doses ≥1000 IU, Long COVID occurred in 4/38 10.5% vs 26/94 27.6% (p = 0.039); for ≥750 IU, 6/48 12.5% vs 24/84 28.6% (p = 0.051). In a matched cohort (43 supplemented, 43 not), Long COVID occurred in 5/43 11.6% vs 14/43 32.6% (p = 0.036); ≥1000 IU: 3/35 8.6% vs 16/51 31.4% (p = 0.016); ≥750 IU: 4/41 9.7% vs 15/45 33% (p = 0.01). In the matched cohort for ≥1000 IU, Long COVID occurred in 3/35 8.5% vs 12/35 34.2% (p = 0.018). Multiple logistic regression reported OR 0.31 (95% CI 0.1–0.94, p = 0.038) for cholecalciferol supplementation in the entire cohort, OR 0.22 (0.06–0.76, p = 0.017) in the matched cohort, and OR 0.16 (0.035–0.7, p = 0.016) in the ≥1000 IU matched cohort. Side effects, withdrawals, and worsening were not reported.

  9. EP280 - ECE_1881 - Chronic cholecalciferol supplementation and adequate vitamin D status are associated with reduced risk of long COVID2026 · compared with another group · 132 in the study
    Summary

    This retrospective observational study included 132 patients with confirmed COVID-19 between March 2020 and May 2021 who had been followed at a tertiary Endocrine Department; median age was 56 years and 49% were male. Of these, 50 (38%) were chronically supplemented with cholecalciferol for a median duration of 38 months and were compared with non-supplemented individuals. Long COVID was defined according to NICE criteria as the persistence of at least two symptoms for more than 12 weeks after recovery, and was diagnosed in 30 patients (22.7%). Long COVID occurred less frequently among supplemented patients compared with non-supplemented individuals (14% vs 28%, P = .086). The difference became statistically significant in patients receiving ≥1000 IU/day (10.5% vs 27.6%, P = .039) and showed a similar trend for doses ≥750 IU/day (12.5% vs 28.6%, P = .051). In the matched cohort (n = 86), Long COVID occurred in 22.1% of patients and was significantly less frequent in those supplemented with cholecalciferol (11.6% vs 32.6%, P = .036); in matched analyses restricted to patients receiving ≥1000 IU/day the figures were 8.5% vs 34.2% (P = .018). In multivariate logistic regression analyses, chronic cholecalciferol supplementation emerged as an independent protective factor in the entire cohort (OR 0.31, P = .038) and the matched cohort (OR 0.22, P = .017). Harms were not reported.

  10. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.2022 · compared with another group · 923 in the study
    Summary

    This longitudinal survey followed recovered COVID-19 patients from Indonesia who were diagnosed by PCR/antigen testing and had recovered less than 30 days after onset. A total of 923 participants’ data were extracted; 168 people were fully vaccinated more than 14 days after a second dose, 41 had received one dose, and 713 were unvaccinated at diagnosis. Participants reported post-COVID symptoms every 30 days for a total of 90 days after onset or diagnosis. The study compared fully vaccinated participants with those who had one dose or were unvaccinated, and compared timing of Favipiravir, vitamin C, vitamin D, and zinc with early initiation or no treatment. For any post-COVID symptoms in 90 days, there was no difference between fully vaccinated and incomplete or unvaccinated individuals after adjustment (aOR 0.74, 95% CI 0.51–1.08, p = 0.118). Complete vaccination was associated with lower odds of chronic cough (aOR 0.527, 95% CI 0.286–0.971, p = 0.040), chronic headache (aOR 0.317, 95% CI 0.163–0.616, p = 0.001), and chronic arthritis (aOR 0.285, 95% CI 0.116–0.703, p = 0.006). Not taking Favipiravir was associated with lower odds of arthritis than taking it within 24 hours (aOR 0.503, 95% CI 0.287–0.882, p = 0.017). Vitamin C later than 72 hours was associated with lower odds of the overall event than vitamin C within 24 hours (aOR 0.63, 95% CI 0.39–0.99, p = 0.048). The combination of micronutrient supplementations and Favipiravir gave no significant effect in seven outcomes. Harms were not reported for this cohort.

  11. Vitamin D and vascular health of Chronic Fatigue Syndrome patients2012 · compared with another group
    Summary

    This study compared Vitamin D with placebo in adults with Chronic Fatigue Syndrome; the text reports 25 participants in the Vitamin D group and 25 in placebo. It does not report why the study was done, where it took place, the dose, route, schedule or duration of Vitamin D, and it does not state whether assignment was randomised or blinded. Outcomes were reported at 2 mths and 6 mths. For the primary outcome, pulse wave velocity, the adjusted treatment effect was -0.2 (95% CI -0.7 to 0.3; p=0.44) at 2 mths and 0.0 (-0.6 to 0.6; p=0.93) at 6 mths. At 2 mths, diastolic blood pressure had an adjusted treatment effect of -5 (-9 to 0; p=0.04); at 6 mths it was -2 (-7 to 2; p=0.34). Other reported comparisons included augmentation index, systolic blood pressure, pulse, FMD, 25OHD, 1,25OHD, calcium, PTH, lipids, HOMA-IR, C-reactive protein, IL-6, TNF-alpha, d-ROMS, BAP, Piper fatigue scale, and hospital anxiety and depression scores. The text lists harms: infections 14 with Vitamin D and 9 with placebo, gastrointestinal 6 and 12, musculoskeletal 2 and 2, dermatological 0 and 1, cardiovascular 1 and 2, new cancer 2 and 0, hypercalcemia 0 and 0, ureteric colic 0 and 0, other 8 and 13, TOTAL 33 and 39, deaths 0 and 0, and hospitalisations 1 and 0. Withdrawals were not reported. The text does not report its authors' conclusion or stated limitations.

  12. Synbiotic Supplementation Improves Quality of Life and Inmunoneuroendocrine Response in Patients with Fibromyalgia: Influence of Codiagnosis with Chronic Fatigue Syndrome.2023 · no comparison group · 15 in the study
    Summary

    This pilot study enrolled 15 women diagnosed with fibromyalgia (FM), 7 with and 8 without a previous diagnosis of chronic fatigue syndrome (CFS), from an FM association in Badajoz, Extremadura (Spain). Participants took the synbiotic Gasteel Plus® as one stick a day, preferably in the morning and mixed in water, for 30 days; each was evaluated at baseline and after the intervention, which lasted one month. The study had no comparison group. Outcomes included body composition by bioimpedance, activity and sleep by accelerometry, validated questionnaires, and IL-8, IL-10, cortisol and DHEA. The paper reports statistically significant improvements in perceived depression, stress, anxiety, fatigue and fibromyalgia impact on daily activity in the total group (p < 0.05); depression and stress improved only in FM patients without CFS, while anxiety, fatigue and FM impact improved only in the FM + CFS group. No significant changes were reported in weight, body fat mass percentage, bone mass, total body water percentage or muscle mass. The visceral fat index decreased statistically significant in FM patients without a codiagnosis of CFS, but without a physiological relevance. Pain, sleep quality and gastrointestinal health improved without statistical significance. The authors state there were no detrimental changes in body composition or sleep parameters.

  13. The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.2022 · no comparison group · 51 in the study
    Summary

    This one-arm, open-labeled study at a single site enrolled 51 eligible patients from 18 states with long-haul COVID, recruited from the local patient population and through social media advertising. Participants took a nutraceutical formulation as one serving twice a day with food for 4 weeks, with no comparison group. They rated the severity of 12 symptoms and their general wellbeing at baseline, 2- and 4-week time points. The authors report that on average all symptoms were significantly milder after 2 weeks, with further improvement after 4 weeks, and that the decrease in severity of all symptoms was statistically significant at both the 2- and 4-week time points. Each symptom was reported as significantly attenuated in 72 to 84% of participants, 46 out of 51 participants reported more symptoms that improved than worsened, 59% reported a noticeable improvement in general wellbeing, and the general profile improved for 88% of participants. Minor adverse events included three patients with vertigo and one patient each with increased anxiety, a gout attack, increased joint pain and reinfection with COVID; among the remaining five participants, one reported feeling a worsening in general wellbeing. The authors state the study had no placebo.

  14. Proposal of a food supplement for the management of post-COVID syndrome.2021 · no comparison group
    Summary

    This paper reviews what is known about post-COVID syndrome and nutritional approaches, and reports a small pilot observational study. People who had recovered from COVID-19 but had post-COVID syndrome with chronic fatigue took a food supplement containing hydroxytyrosol, acetyl L-carnitine and vitamins B, C and D, and their perceived fatigue was assessed. The abstract gives no number of participants, no length of treatment, no fatigue scores and no side effects. The authors write that the results suggest the supplement could go on to clinical trials.

  15. Improvement in Long COVID Brain Fog After Benfotiamine and Methylcobalamin Supplementation: Case Report Series and Review of the Literature2026 · case report · 3 in the study
    Summary

    This case series reports three people with Long COVID-related cognitive dysfunction (brain fog); one also had chronic fatigue syndrome/myalgic encephalomyelitis. All three self-administered an oral proprietary formulation of benfotiamine and methylcobalamin at differing doses: benfotiamine 150 mg, 300 mg, or 300 mg twice daily, with methylcobalamin 500 mcg, 1,000 mcg, or 12 mcg per day. There was no comparison group. Outcomes were patient-reported; no baseline thiamine or vitamin B12 biomarkers and no cognitive assessments were obtained before supplementation. Each patient described a noticeable benefit within a brief period ranging from several days to several weeks. In case 1, improvement in energy and mental clarity and resolution of brain fog were reported within three days. In case 2, improvements in mental clarity, executive function and confidence were reported within six weeks; after five weeks without the supplement, cognitive dysfunction recurred, and improved cognitive function returned within four to six weeks of resuming it. In case 3, brain fog and joint pain improved within 10 days, radicular pain resolved and dizziness improved by approximately 85% after 30 days. No serious adverse effects were reported by any patient; case 1 reported no adverse effects. The authors state the observations are hypothesis-generating and cannot establish causality.

  16. HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
    Summary

    This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.

  17. Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
    Summary

    This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.

  18. Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review.2025 · combination: given with other treatments · 1,243 in the study · 1,171 with outcome data
    Summary

    This retrospective preliminary observation and narrative review asked whether nutrient supplements affected long COVID in children. It was a retrospective sub-analysis of a previously published prospective follow-up cohort at a Post-COVID clinic in a third-level hospital in Rome, Italy, from February 2020 to October 2022. During the study period 1243 patients were enrolled; 1171 were in the six-month follow-up table. Children with persistent, disabling symptoms at three months after infection received oral lactoferrin and/or a Multi-Element Product (MEP) as chewable tablets once a day for 90 days. Treatment groups were MEP plus lactoferrin (152 started), lactoferrin alone (18), and MEP alone (9). The outcome was persistence of long COVID at six months following initial infection. As reported, MEP alone (OR 5.7, 95% CI 3.8–8.5) and MEP plus lactoferrin (OR 5.06, 95% CI 3.3–7.6) were associated with a lower risk of long COVID at six months than lactoferrin alone (OR 7.6, 95% CI 5.1–11.4). For therapy started six months or longer after infection, no statistically significant associations were found with Long Covid resolution. Harms were not reported. The authors state the study was retrospective and had no control group, so causality and spontaneous improvement cannot be distinguished.

  19. Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial.2025 · combination: given with other treatments · 151 randomised
    Summary

    This single-site randomized trial in Cleveland enrolled 151 adults with long COVID, defined as at least two moderate symptoms at least 3 months after COVID-19. Participants were randomized 2:1 to 24 weeks of daily 240 µg vitamin K2 (MK-7) plus 2000 IU vitamin D3 (n = 98) or standard of care (n = 53). The trial measured long COVID symptoms using the RECOVER Long COVID Research Index and symptom counts, plus inflammatory, metabolic and gut biomarkers. At 24 weeks, the vitamin K2/D3 arm had a 7.1% decrease in the proportion with an LC Index ≥12 versus a 7.2% increase in the standard-of-care arm (p = 0.01). The average number of LC symptoms remained stable in the vitamin K2/D3 arm but increased in the standard-of-care arm (p = 0.03); at month six the averages were 8.8 ± 5.6 and 10.9 ± 5.8. The paper reports reductions in oxidized LDL, sTNF-RI, sCD163 and (1,3)-β-d-glucan in the vitamin K2/D3 arm compared with standard of care (p < 0.01). The paper also states fasting lipids, glucose and HOMA-IR remained stable with no significant between-arm changes, but separately reports a fasting glucose between-arm difference. Over the study period, 91 participants (62 vitamin arm and 29 standard-of-care arm) reported 213 adverse events; 28 participants discontinued, two related to adverse events (headache Grade 1 and myocardial infarction), and no adverse events were attributed to the study intervention. The authors state the study did not assess longitudinal symptom severity, the control arm received no placebo, unmeasured confounding such as diet and physical activity was not accounted for, and the intervention was confined to 24 weeks.

  20. Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study2017 · combination: given with other treatments · 10 in the study
    Summary

    This 16-week open-label pilot study examined a combination nutraceutical of mitochondrial agents in 10 patients with chronic fatigue syndrome recruited through clinicians and based at The Melbourne Clinic in Melbourne, Australia. Participants received twice-daily dosing of Co Q10, alpha lipoic acid, N-acetylcysteine, Acetyl L-carnitine, B vitamins and co-factors for 16 weeks, with no placebo comparison. Assessments occurred at baseline, W4, W8, W12 and W16 and included the Chalder Fatigue Scale (CFQ), MADRS, ISI, PGI, CGI-S, CGI-I, WSAS and SF-12. Mean total CFQ scores fell from 22.0 (6.07) at baseline to 12.6 (7.46) at Week 16 (F(4,29) = 6.31, p < 0.001); the baseline-to-Week 4 mean difference was 7.66 (p < 0.01). Nine of 11 CFQ items showed significant improvement, while memory (item 11) and problems starting things (item 4) did not. ISI (p = 0.017) and CGI-I (p = 0.014) improved; MADRS (p = 0.225), PGI (p = 0.33), CGI-S (p = 0.150), WSAS (p = 0.095) and SF-12 measures did not change significantly. Adverse events included headaches/migraines (n = 3), minor gastritis (n = 4), loss of appetite/feeling of fullness (n = 1), brief tachycardia (n = 1) and skin pigmentation on the forehead (n = 1); no serious adverse events were noted, and no participants withdrew due to adverse events. Two participants (20%) withdrew before termination, at week four and week twelve, due to work commitments.

  21. The Efficacy of Multivitamin, Vitamin A, Vitamin B, Vitamin C, and Vitamin D Supplements in the Prevention and Management of COVID-19 and Long-COVID: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether vitamin supplementation prevents or manages COVID-19 and/or long-COVID. It included 37 articles, of which 20 were meta-analyzed; eligible studies were randomized clinical trials from any country comparing vitamin administration with placebo or standard of care. The review reported pooled all-cause mortality for vitamin C (n = 9, RR = 0.84; 95% CI: 0.72–0.97, I2 = 0.0%) and a significant ICU-hospitalized subgroup result (n = 3, RR = 0.85; 95% CI: 0.73–0.99, I2 = 0.0%). For vitamin D, overall mortality did not show a significant reduction (n = 10, RR = 0.86; 95% CI: 0.59–1.24, I2 = 29%), while multiple administrations showed a positive effect (n = 7, RR = 0.67; 95% CI: 0.49–0.91, I2 = 0%). Individual findings were mixed: Leal-Martínez et al. reported lower mortality and higher saturation, Hakamifard et al. found no difference except a lower respiratory rate, Somi et al. found no significant difference in listed outcomes, and Abroug et al. reported longer viral RNA conversion in the supplemented group. Side effects were not detected in five trials or did not differ in four RCTs; one of six studies found a higher proportion of events. The authors state limitations include heterogeneity in recruitment, treatment protocols, and outcome definitions.

  22. Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
    Summary

    This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.

  23. Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary and nutrition interventions affect patient-centred outcomes in adults with CFS/ME. Medline, Cinahl and Scopus were searched from 1994 to May 2016; 17 studies were included, covering 14 different interventions. Included studies were mostly small and from multiple countries. Interventions included ubiquinol-10 150 mg/day for 12 weeks versus placebo; NADH 200 mg/day plus CoQ10 20 mg/day for 8 weeks versus placebo; high cocoa polyphenol chocolate for 8 weeks versus low-polyphenol chocolate; NADH 10 mg/day for 4 weeks versus placebo; probiotics; and an elimination diet. Outcomes were fatigue, quality of life, physical activity and psychological wellbeing. The review reports that many studies did not show therapeutic benefit; improvements in fatigue were observed for NADH, probiotics, high cocoa polyphenol rich chocolate, and a combination of NADH and coenzyme Q10. One included study (n=10) reported decreased fatigue with high cocoa polyphenol chocolate, and one (n=26) reported within-group benefit for NADH versus placebo. Side-effect counts and counts of people who worsened or stopped were not reported. The authors conclude there is insufficient evidence for nutritional supplements and elimination or modified diets to relieve CFS/ME symptoms.

  24. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis.2017 · systematic review
    Summary

    This systematic review and meta-analysis examined vitamin and mineral status in chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS). The authors searched PubMed, EMBASE, Web of Knowledge, and PsycINFO from January 1st 1994 for CFS patients and 1990 for FMS patients until March 1st 2017. They included 5 RCTs and 40 observational studies in the qualitative synthesis; 27 studies were included in meta-analyses. The RCTs tested magnesium citrate plus amitriptyline versus amitriptyline only, a polynutrient supplement versus placebo, vitamin C and E treatment combined with exercise versus exercise only, cholecalciferol versus placebo, and cholecalciferol versus placebo. Outcomes included FMS symptoms, fatigue, physical activity, pain, depression, anxiety, and health-related measures. One trial reported that amitriptyline plus magnesium supplementation gave better results on all measured outcomes than amitriptyline alone; one trial found a significant treatment effect on pain intensity for cholecalciferol versus placebo. Other RCTs reported no significant difference or no improvement in symptoms. Side-effect counts and discontinuation were not reported for the included trials. The authors state that most published RCTs found no treatment effect of vitamin and mineral supplementation on clinical parameters.

  25. Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.

  26. Pediatric post-acute sequelae of SARS-CoV-2 infection in Taiwan: Insights from the DISCOVER cohort.2026 · review
    Summary

    This review summarizes the DISCOVER cohort in Taiwan, which was set up to study pediatric post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. Within the cohort, the authors describe a double-blind randomized controlled trial in 33 children with PASC. Children received either oral vitamin D 2000 IU/day or placebo for six months. The main outcome recorded here was overall symptom burden measured with CSSI-24. The review reports that vitamin D supplementation led to a significant reduction in overall CSSI-24 symptom burden compared with placebo. It also reports that improvements were observed across several neuropsychiatric, respiratory, and cardiovascular symptoms, whereas no symptom reached statistical significance in the placebo group. The text provided did not report side effects, withdrawals, or worsening. The authors describe the trial findings as preliminary and early randomized evidence that vitamin D supplementation may improve certain post-acute symptoms in children. They conclude that vitamin D supplementation has emerged as a promising therapeutic candidate that may help reduce symptom burden and systemic inflammation, particularly in genetically susceptible children, but state that larger studies are required to confirm these findings.

  27. Impact of nutrition on long COVID.2026 · review
    Summary

    This narrative review examined nutritional and exercise interventions for long COVID; it did not report its own cohort. It describes a single-site RCT with n = 151 participants; n = 98 received VitK2/D3 and n = 53 received standard of care, and participants who received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. A randomized, double-blind, placebo-controlled trial with n = 80 patients (n = 40 post COVID patients; n = 40 placebo) gave 60 000 IU of Vitamin D weekly for 8 weeks; the vitamin D group showed significant improvements in CFQ, DASS-anxiety and ACE, but no significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels; Table 2 entry 11 reported this vitamin D supplementation with very low side effects. A multicentre trial with n = 144 patients (n = 71 vitamin D3 group; n = 71 placebo group) gave a single oral dose of 200 000 IU Vitamin D3 and found no significant differences between Vit D3 and placebo group for listed symptoms and quality of life upto 1 year of follow up. Probiotic mixture VSL#3® reduced fatigue and significantly improved physical functioning and gasterointestinal symptoms. Stopping or worsening was not reported. The review states limitations in trial design.

  28. Vitamin D in Infectious Diseases: A Narrative Review Focusing on COVID-19, Long COVID, and Influenza.2026 · review
    Summary

    This narrative review examined literature published between 2020 and 2025 on vitamin D in COVID-19, long COVID, and influenza. For long COVID, it described di Filippo et al. (2023), which evaluated 100 COVID-19 survivors 6 months after hospitalization: long COVID patients had lower median serum 25(OH)D than those without long-term symptoms (20.1 ng/mL vs 23.2 ng/mL). Among patients deficient at illness and remained deficient, those with long COVID had follow-up levels of 12.7 ng/mL vs 15.2 ng/mL without long COVID. Each 1 ng/mL decrease in 25(OH)D was associated with a 9% increase in odds of long COVID. A prospective study by Matangkha et al. (2025) reported median 25(OH)D of 21.5 ng/mL in patients who developed long COVID vs 25.5 ng/mL in those who did not; patients with sufficient levels had odds of long COVID about 5.8 times lower than deficient patients (adjusted OR 5.80, 95% CI 2.10–16.13), and the adjusted incidence rate ratio for number of long COVID symptoms was about 3.3. A post hoc analysis of a trial of 200,000 IU single-dose vitamin D vs placebo in acute COVID-19 found no difference in long COVID symptoms after 1 year. The review stated every trial showed a good safety profile, but a few trials suggested extremely high doses might suppress immune function. Limitations include observational designs, small cohorts, confounding, and reverse causality.

  29. Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
    Summary

    This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.

  30. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

  31. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  32. A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
    Summary

    This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.

  33. Post-COVID Condition and Neuroinflammation: Possible Management with Antioxidants.2025 · review
    Summary

    This narrative review examined antioxidant-based interventions as potential therapeutic strategies for post-COVID condition (PCC), also called long COVID, in the context of neuroinflammation and oxidative stress. The review searched major scientific databases and included 199 references; it reports no primary participants, enrolled or analysed count, or comparison group of its own. It describes cited trials: PEA-LUT (palmitoylethanolamide co-ultramicronized and luteolin for 90 days) improved olfactory threshold in 130 patients with PCC and persistent olfactory impairment; the same compound, given orally bid for eight weeks, reduced brain fog in 39 patients; Bioarginina C (L-arginine and liposomal vitamin C for 28 days) reduced fatigue in 23 patients; an oral antioxidant food supplement (2 per day for 2 months) reduced fatigue in 33 patients; and vitamin D (60,000 IU weekly for 8 weeks) alleviated anxiety and cognitive symptoms in 80 patients. The review also states that higher doses of NAC may result in nausea, vomiting, skin rash, pruritus and erythema, and that vitamin D carries a risk of hypercalcemia. The authors describe the evidence as preliminary and fragmented.

  34. Nutritional Interventions, Nutraceuticals, and Metabolic Therapies for Long COVID and Post-COVID-19 Vaccination Syndrome2025 · review
    Summary

    This REVIEW ARTICLE summarizes nutritional, nutraceutical, and metabolic treatments for long COVID/post-acute COVID-19 syndrome (PACS) and post-COVID-19 vaccination syndrome (PCVS); it reports no own cohort or setting. For low-dose naltrexone (LDN), O’Kelly et al. reported benefits in 52 long COVID patients over a 2–3-month period, including improvement in self-reported activities of daily living, energy, pain, concentration, sleep disturbance, and overall recovery, and decreased coughing, chest tightness, personality changes, low mood, and joint discomfort; pain improved most. In observational research by Glynne et al., 72% of individuals with long COVID who underwent antihistamine treatment showed noticeable but gradual symptom improvement, except dysautonomia. A nonrandomized controlled clinical experiment found 6 weeks of oral anhydrous enol-oxaloacetate (AEO) decreased physical and mental fatigue in ME/CFS and long COVID; ME/CFS patients receiving 500 and 1000 mg twice a day and three times a day improved from 21.7 to 33.3% versus baseline, and long-COVID fatigue improved up to 46.8% over baseline. A randomized controlled clinical trial reported vitamins K2/D3 improved GI and inflammatory markers, the RECOVER long COVID index, and other long COVID symptoms. Among 668 responders with long COVID, between 40 and 70% reported some symptom improvement after nattokinase, serrapeptase, or lumbrokinase; 13 out of 14 long COVID patients in a case series who fasted for an extended period improved. The review notes increased free zinc may negatively affect antibody production and excess zinc is harmful. The authors state additional large-scale controlled studies and future randomized controlled trials are needed.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime